Compare Chart Industries Inc (GTLS) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chart Industries Inc vs Eli Lilly And Co — how do they compare? Chart Industries Inc trades at $209.97 (market cap $10.05B), while Eli Lilly And Co trades at $1,173.2 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 102.5× Chart Industries Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Chart Industries Inc pays none. Which is the better fit depends on your goals.
| GTLS | LLY | |
|---|---|---|
Market Cap | $10.05B | $1.03T |
Sector | Technology | Health |
52-Week High | $209.91 | $1.24K |
52-Week Low | $167.29 | $625.65 |
Enterprise Value | $13.57B | $1.07T |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GTLS trades at $209.97, up 0.03% on the day, with a bullish technical signal driven by moving averages. The company reported $4.26B revenue for 2025 but missed earnings estimates for three consecutive quarters, with a net income margin of -0.62%. Recent news highlights Baker Hughes' pending $13.6B acquisition, which received conditional EU approval in July 2026.
The outlook is mixed: strong analyst support (54% buy ratings) and acquisition potential offer upside, but weak profitability and earnings misses pose risks. Investors should weigh the acquisition's completion against fundamental challenges in the near term.
LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.
Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chart Industries Inc
Chart Industries is a leading manufacturer of highly engineered cryogenic equipment. Its products are used throughout the liquid gas supply chain, including clean energy applications like hydrogen and LNG.
Read more on GTLS →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
